Patent extension efforts for Lodine, Relafen, Claritin criticized by Rep. Stark.
This article was originally published in The Tan Sheet
AMERICAN HOME PRODUCTS' LODINE PATENT EXTENSION EFFORTS CRITICIZED by Rep. Pete Stark (D-Calif.) in a Sept. 24 "Dear Colleague" letter. Stark, who also cited efforts to enact two-year patent extensions for Schering-Plough's non-sedating antihistamine Claritin and SmithKline Beecham's NSAID Relafen, argued that these companies "are hoping that we will force the American public into subsidizing a multimillion dollar special interest `sweetheart' deal in our rush to end the 104th Congress."
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC